MX2022009818A - Combinaciones terapeuticas que comprenden inhibidores de proteasa 1 de procesamiento especifico de ubiquitina (usp1) e inhibidores de poli (adp-ribosa) polimerasa (parp). - Google Patents
Combinaciones terapeuticas que comprenden inhibidores de proteasa 1 de procesamiento especifico de ubiquitina (usp1) e inhibidores de poli (adp-ribosa) polimerasa (parp).Info
- Publication number
- MX2022009818A MX2022009818A MX2022009818A MX2022009818A MX2022009818A MX 2022009818 A MX2022009818 A MX 2022009818A MX 2022009818 A MX2022009818 A MX 2022009818A MX 2022009818 A MX2022009818 A MX 2022009818A MX 2022009818 A MX2022009818 A MX 2022009818A
- Authority
- MX
- Mexico
- Prior art keywords
- usp1
- parp
- inhibitors
- ubiquitin
- specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente descripción proporciona combinaciones terapéuticas que comprenden (i) un inhibidor de la proteasa 1 de procesamiento específico de ubiquitina (USP1) y (ii) un inhibidor de poli ADP-ribosa polimerasa (PARP), o una sal, hidrato, solvato, sólido amorfo o polimorfo farmacéuticamente aceptable del mismo, en donde el inhibidor de USP1 comprende (I), (II) o (III), o sales, hidratos, solvatos, sólidos amorfos o polimorfos farmacéuticamente aceptables del mismo. La presente descripción también está dirigida al uso de las combinaciones para inhibir una proteína USP1 y/o PARP y/o para tratar un trastorno que responde a la inhibición de las proteínas USP1 y/o PARP y la actividad de USP1 y/o PARP. Las combinaciones de la presente descripción son especialmente útiles para tratar el cáncer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062976864P | 2020-02-14 | 2020-02-14 | |
US202063032245P | 2020-05-29 | 2020-05-29 | |
US202163146937P | 2021-02-08 | 2021-02-08 | |
PCT/US2021/017912 WO2021163530A1 (en) | 2020-02-14 | 2021-02-12 | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009818A true MX2022009818A (es) | 2022-09-05 |
Family
ID=77291879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022009818A MX2022009818A (es) | 2020-02-14 | 2021-02-12 | Combinaciones terapeuticas que comprenden inhibidores de proteasa 1 de procesamiento especifico de ubiquitina (usp1) e inhibidores de poli (adp-ribosa) polimerasa (parp). |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230277533A1 (es) |
EP (1) | EP4103165A4 (es) |
JP (1) | JP2023514568A (es) |
KR (1) | KR20220140732A (es) |
CN (1) | CN115066235A (es) |
AU (1) | AU2021218805A1 (es) |
CA (1) | CA3168009A1 (es) |
IL (1) | IL295149A (es) |
MX (1) | MX2022009818A (es) |
TW (1) | TW202140026A (es) |
WO (1) | WO2021163530A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220140732A (ko) * | 2020-02-14 | 2022-10-18 | 케이에스큐 세러퓨틱스 인코포레이티드 | 유비퀴틴-특이적-프로세싱 프로테아제 1(usp1) 억제제 및 폴리 (adp-리보스) 중합효소(parp) 억제제를 포함하는 치료학적 조합물 |
TW202233621A (zh) | 2020-10-30 | 2022-09-01 | 美商Ksq治療公司 | 經取代吡唑并嘧啶之固態形式及其用途 |
WO2023066299A1 (en) * | 2021-10-19 | 2023-04-27 | Impact Therapeutics (Shanghai) , Inc | Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof |
AU2022387669A1 (en) * | 2021-11-12 | 2024-05-16 | Insilico Medicine Ip Limited | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
CA3235765A1 (en) | 2021-11-12 | 2023-05-19 | Jianping Wu | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
WO2023147311A1 (en) * | 2022-01-25 | 2023-08-03 | KSQ Therapeutics, Inc. | Ubiquitin-specific-processing protease 1 (usp1) inhibitors for the treatment of solid tumors |
WO2024061213A1 (zh) * | 2022-09-20 | 2024-03-28 | 正大天晴药业集团股份有限公司 | 用作泛素-特异性蛋白酶抑制剂的羰基稠合杂环衍生物 |
WO2024064883A2 (en) * | 2022-09-23 | 2024-03-28 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and parp1-selective inhibitors |
WO2024086790A1 (en) | 2022-10-21 | 2024-04-25 | Exelixis, Inc. | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2797719C (en) * | 2010-04-30 | 2019-11-26 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of usp1 deubiquitinating enzyme activity |
GB201519573D0 (en) * | 2015-11-05 | 2015-12-23 | King S College London | Combination |
WO2018165615A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
JP2020512347A (ja) * | 2017-03-27 | 2020-04-23 | テサロ, インコーポレイテッド | ニラパリブ製剤 |
MX2021007179A (es) * | 2018-12-20 | 2021-09-28 | Ksq Therapeutics Inc | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1). |
WO2021146378A1 (en) * | 2020-01-15 | 2021-07-22 | KSQ Therapeutics, Inc. | Compositions of substituted pyrazolopyrimidines and uses thereof |
KR20220140732A (ko) * | 2020-02-14 | 2022-10-18 | 케이에스큐 세러퓨틱스 인코포레이티드 | 유비퀴틴-특이적-프로세싱 프로테아제 1(usp1) 억제제 및 폴리 (adp-리보스) 중합효소(parp) 억제제를 포함하는 치료학적 조합물 |
TW202233621A (zh) * | 2020-10-30 | 2022-09-01 | 美商Ksq治療公司 | 經取代吡唑并嘧啶之固態形式及其用途 |
-
2021
- 2021-02-12 KR KR1020227027461A patent/KR20220140732A/ko unknown
- 2021-02-12 JP JP2022548896A patent/JP2023514568A/ja active Pending
- 2021-02-12 WO PCT/US2021/017912 patent/WO2021163530A1/en unknown
- 2021-02-12 CA CA3168009A patent/CA3168009A1/en active Pending
- 2021-02-12 MX MX2022009818A patent/MX2022009818A/es unknown
- 2021-02-12 IL IL295149A patent/IL295149A/en unknown
- 2021-02-12 AU AU2021218805A patent/AU2021218805A1/en active Pending
- 2021-02-12 US US17/904,159 patent/US20230277533A1/en active Pending
- 2021-02-12 CN CN202180013564.7A patent/CN115066235A/zh active Pending
- 2021-02-12 EP EP21754160.6A patent/EP4103165A4/en active Pending
- 2021-02-17 TW TW110105371A patent/TW202140026A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021218805A1 (en) | 2022-09-01 |
CN115066235A (zh) | 2022-09-16 |
US20230277533A1 (en) | 2023-09-07 |
EP4103165A4 (en) | 2024-02-28 |
TW202140026A (zh) | 2021-11-01 |
WO2021163530A1 (en) | 2021-08-19 |
JP2023514568A (ja) | 2023-04-06 |
EP4103165A1 (en) | 2022-12-21 |
CA3168009A1 (en) | 2021-08-19 |
KR20220140732A (ko) | 2022-10-18 |
IL295149A (en) | 2022-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022009818A (es) | Combinaciones terapeuticas que comprenden inhibidores de proteasa 1 de procesamiento especifico de ubiquitina (usp1) e inhibidores de poli (adp-ribosa) polimerasa (parp). | |
MX2021007179A (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1). | |
US9957270B2 (en) | Fused pyrimidine-based hydroxamate derivatives | |
TW200613306A (en) | Imidazotriazines as protein kinase inhibitors | |
RU2763346C2 (ru) | Фармацевтическая композиция для предупреждения или лечения острого миелоидного лейкоза или метастатического рака молочной железы | |
EP3746124A1 (en) | Compounds and uses thereof | |
SG132683A1 (en) | Imidazopyrazine tyrosine kinase inhibitors | |
GB2392154B (en) | Protein Kinase Inhibitors | |
ATE489360T1 (de) | Inhibitoren der histon-deacetylase | |
ECSP088387A (es) | Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms | |
MXPA04002397A (es) | Inhibidores de histona deacetilasa. | |
NZ514450A (en) | Use of dipeptidyl peptidase IV inhibitors for promoting growth | |
IL165262A0 (en) | Kinase inhibitors | |
YU61402A (sh) | Pirol substituisani 2 indolinon protein kinazni inhibitori | |
HK1057206A1 (en) | Quinazoline derivatives as kinase inhibitors | |
BR0317183A (pt) | Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno | |
ATE514674T1 (de) | Inhibitoren für histone-deacetylase | |
PL1737451T3 (pl) | Monocykliczne heterocykle jako inhibitory kinazy | |
EP2205088A4 (en) | NAPHTHALIN-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | |
ZA202201329B (en) | Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders | |
MX2022009059A (es) | Compuestos heterociclicos novedosos utiles como inhibidores selectivos de aurora a. | |
DK1543010T3 (da) | N-substituerede hydromorphoner og anvendelse deraf | |
MX2019010096A (es) | Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa. | |
MY147226A (en) | Method of inhibiting c-kit kinase | |
MX2022015679A (es) | Inhibidor de tyk-2. |